We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

97 hedge funds and large institutions have $1.14B invested in Aclaris Therapeutics in 2021 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 32 increasing their positions, 26 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

479% more capital invested

Capital invested by funds: $198M → $1.14B (+$947M)

400% more funds holding in top 10

Funds holding in top 10: 3 → 15 (+12)

94% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 17

52% more call options, than puts

Call options by funds: $6.4M | Put options by funds: $4.21M

23% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 26

18% more funds holding

Funds holding: 82 → 97 (+15)

13.27% more ownership

Funds ownership: 74.4% → 87.68% (+13%)

Holders
97
Holders Change
+15
Holders Change %
+18.29%
% of All Funds
1.7%
Holding in Top 10
15
Holding in Top 10 Change
+12
Holding in Top 10 Change %
+400%
% of All Funds
0.26%
New
33
Increased
32
Reduced
26
Closed
17
Calls
$6.4M
Puts
$4.21M
Net Calls
+$2.19M
Net Calls Change
-$645K

Top Buyers

1
FCMI
Foresite Capital Management IV
California
+$47.9M
2
CAM
Cormorant Asset Management
Massachusetts
+$39.1M
3
VA
VR Adviser
New York
+$34.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$25.3M
5
Citadel Advisors
Citadel Advisors
Florida
+$25.1M

Top Sellers

1
ECM
Endurant Capital Management
California
-$13.1M
2
SI
Sofinnova Investments
California
-$12.4M
3
EC
EcoR1 Capital
California
-$9.77M
4
SB
Samsara BioCapital
California
-$6.65M
5
CC
Commodore Capital
New York
-$6.03M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$9.5M +$1.01M +51,888 +16%
SSA
27
Schonfeld Strategic Advisors
New York
$9.26M +$1.18M +60,492 +20%
Millennium Management
28
Millennium Management
New York
$8.65M +$2.63M +134,321 +64%
SCM
29
Silverarc Capital Management
Massachusetts
$8.49M +$6.59M +336,737 New
Point72 Asset Management
30
Point72 Asset Management
Connecticut
$8.26M +$6.41M +327,800 New
ACP
31
Acuta Capital Partners
California
$8.01M +$6.21M +317,730 New
SAM
32
Stenahm Asset Management
Guernsey
$7.14M -$4.43M -226,500 -44%
Deutsche Bank
33
Deutsche Bank
Germany
$6.52M +$3.78M +193,083 +294%
Nomura Holdings
34
Nomura Holdings
Japan
$6.05M +$4.7M +240,233 New
AAA
35
Affinity Asset Advisors
New York
$5.6M +$4.35M +222,267 New
BCM
36
Bridgeway Capital Management
Texas
$5.4M -$491K -25,100 -10%
EI
37
EAM Investors
California
$5.17M +$4.01M +205,295 New
State Street
38
State Street
Massachusetts
$4.86M +$2.25M +114,902 +147%
IC
39
Ikarian Capital
Texas
$4.74M -$2.19M -111,800 -37%
PVI
40
Pura Vida Investments
New York
$4.43M +$2.46M +125,799 +252%
Two Sigma Investments
41
Two Sigma Investments
New York
$4.39M +$1.72M +87,984 +102%
TLP
42
Tri Locum Partners
New York
$4.14M +$3.21M +164,199 New
HF
43
HRT Financial
New York
$3.83M +$2.97M +152,119 New
JGC
44
J. Goldman & Co
New York
$3.65M +$1.95M +99,911 +222%
ECM
45
ExodusPoint Capital Management
New York
$3.55M -$1.6M -81,793 -37%
EGI
46
EAM Global Investors
California
$3.06M +$2.38M +121,563 New
Goldman Sachs
47
Goldman Sachs
New York
$3.04M +$1.84M +94,275 +358%
Bank of New York Mellon
48
Bank of New York Mellon
New York
$2.8M +$128K +6,537 +6%
Northern Trust
49
Northern Trust
Illinois
$2.74M +$354K +18,108 +20%
FCM
50
Farallon Capital Management
California
$2.52M +$1.96M +100,000 New
1
2
3 4 5

ACRS Hedge Fund Activity: Q1 2021 in Review

97 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2021, worth a combined $1.14B — up 479% from $198M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new ACRS positions and 17 closed out — a net gain of 16 holders — while 32 added to existing stakes and 26 trimmed.

The largest buyer was Foresite Capital Management IV, adding an estimated $47.9M. The largest seller was Endurant Capital Management, cutting an estimated $13.1M.

  • 97 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2021, up from 82 in Q4 2020.
  • Funds reported $1.14B of Aclaris Therapeutics stock for Q1 2021, up 479% quarter-over-quarter.
  • 33 funds opened new Aclaris Therapeutics positions in Q1 2021 and 17 closed out, a net change of +16 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2021 was Foresite Capital Management IV, an estimated $47.9M added.
  • The largest Aclaris Therapeutics seller in Q1 2021 was Endurant Capital Management, an estimated $13.1M sold.

Based on aggregated 13F filings for Q1 2021.